Yu John S's Form 4 filing
Kairos Pharma, LTD. (KAPA) · filed Nov 21, 2024
- Accession no.
- 0001493152-24-047261
- Filed
- Nov 21, 2024
- Trade date
- Nov 20, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $5.76K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yu John SCIK 0001550545 | Director, Officer (CEO and Chairman), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 20, 2024 | COMMON STOCK | PPurchaseAcquired | +4,000 | $1.44 | +$5,760 | 5,341,837 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.